Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL

Victory Capital Management Inc. decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 479,672 shares of the specialty pharmaceutical company’s stock after selling 29,084 shares during the quarter. Victory Capital Management Inc. owned about 1.52% of Collegium Pharmaceutical worth $16,784,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of COLL. Federated Hermes Inc. increased its holdings in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares in the last quarter. Hantz Financial Services Inc. grew its position in Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. NewEdge Advisors LLC increased its stake in Collegium Pharmaceutical by 304.6% during the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares in the last quarter. Finally, EMC Capital Management purchased a new position in Collegium Pharmaceutical in the second quarter worth about $97,000.

Analysts Set New Price Targets

A number of research firms have recently commented on COLL. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Needham & Company LLC reduced their target price on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Barclays lowered their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Insider Activity

In related news, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Trading Down 1.8%

NASDAQ:COLL opened at $36.61 on Wednesday. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $50.79. The business has a fifty day moving average price of $45.03 and a 200-day moving average price of $42.11. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 21.41 and a beta of 0.67. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The company had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. During the same period in the prior year, the firm posted $1.77 EPS. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.